Alligator Bioscience AB is a biotechnology company, which engages in the development of novel immuno-oncology drugs. The firm specializes in the development of tumor-directed immunotherapies. Its pipeline includes Mitazalimab, ATOR-1017, ALG.APV-527, Neo-X-Prime, and other research projects. The company was founded by Carl Arne Krister Borrebaeck in 2001 and is headquartered in Lund, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company